Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Atopic Dermatitis (AD), Eczema
In brief
This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD). Healthy volunteers will participate in Single Ascending Dose (SAD) Cohorts 1-5. Participants with moderate to severe AD will be enrolled in SAD Cohorts 6-7, Multiple Ascending Dose (MAD) Cohorts, and a Proof-of-Concept (POC) expansion cohort.
Key facts
- Study ID
- NCT07453602
- Run by
- Arcutis Biotherapeutics, Inc.
- People needed
- 125
- Starts
- 2026-03-02
- Expected to finish
- 2028-04-01
- Last updated by the study team
- 2026-05-22
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Site 101 — Fair Lawn, New Jersey, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.